Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target

Lee, Su Jin*,†; Byeon, Sun-Ju; Lee, Jeeyun*; Park, Se Hoon*; Park, Joon Oh*; Park, Young Suk*; Kang, Won Ki*; Lim, Ho Yeong*; Kim, Kyoung-Mee; Kim, Seung Tae*

doi: 10.1097/CJI.0000000000000283
Basic Studies
Buy

We performed a prospective immunohistochemical analysis of lymphocyte activation gene 3 (LAG3) for 430 consecutive patients with advanced gastrointestinal, genitourinary, or rare cancers between June 2012 and March 2016. Most patients (428/430, 99.5%) were evaluable for LAG3 expression by immunohistochemistry. In total, 18.5% (79/428) of the evaluated cancers expressed LAG3, including pancreatic cancer (33.3%, 2/6), gastric cancer (24.7%, 21/85), colorectal cancer (23.6%, 48/203), melanoma (12.5%, 1/8), genitourinary cancer (9.5%, 4/46), biliary tract cancer (6.3%, 1/16), and sarcoma (5.4%, 2/37), but not miscellaneous (0.0%, 0/14) or hepatocellular (0.0%, 0/15) cancer. Among 149 metastatic colorectal cancer patients, there was no statistically significant difference in sex, age, primary tumor site, pathologic differentiation, KRAS and NRAS status, BRAF status, and microsatellite instability according to LAG3 status (expressed vs. nonexpressed). Among 53 metastatic gastric cancer patients, LAG3 was only significantly associated with Epstein Barr virus status (P=0.042). Our results add to the emerging literature on LAG3 expression in various cancer types and support the need for extended clinical exploration of this target for immunotherapy.

*Department of Medicine, Division of Hematology-Oncology

Department of Pathology & Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine

Department of Internal Medicine, Division of Hematology-Oncology, Ewha Woman’s University College of Medicine, Seoul, Korea

S.J.-L. and S.J.B.: contributed equally.

Reprints: Seung Tae Kim, Department of Medicine, Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea (e-mail: shty1@skku.edu).

Received July 17, 2018

Accepted April 8, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.